Biotechnology company Isofol Medical has announced that the European Patent Office intends to grant a new product patent for its drug candidate arfolitixorin. Once the patent is issued, the company will enjoy patent protection in Europe until 2043.
The company also intends to seek extended protection in the United States and Japan, among other regions.
"The new patent protection significantly strengthens our intellectual property position, extending well into the mid-2040s. This supports the long-term development and commercialization of arfolitixorin and substantially increases the project's value," commented CEO Petter Segelman Lindqvist.
